China's Ascletis submits drug marketing applications in Europe, stock soars

Ascletis Pharma

14/02/2022 04:46

** Shares of Chinese biotech group Ascletis Pharma Inc
 1672.HK  jump as much as 18.5% to HK$4.94, the biggest daily
percentage gain since Jan. 19
    ** Stock hits the highest since Feb. 9, and on track to snap
three straight sessions of losses
    ** Zhejiang, China-based co says marketing authorisation
applications for its ritonavir have been submitted to Germany,
France, Ireland and the United Kingdom, and more applications
will soon be submitted to countries in Europe, North America and
Asia Pacific (https://bit.ly/3sHVee5)
    ** Company says it has been in discussions with domestic and
international companies, including major multi-national
pharmaceutical firms, for the commercial supplies of ritonavir
in China and globally
    ** Says annual production capacity of its oral ritonavir
tablet, a pharmacokinetic booster of multiple oral antiviral
drugs targeting viral proteases, has been expanded to 100
million tablets and can be expanded further based on demand
    ** Hang Seng Commerce & Industry Index  .HSNC  falls 1.5%
and healthcare index  .HSCIH  eases 0.3%
    ** Hang Seng Composite Index  .HSCI  and the benchmark Hang
Seng Index  .HSI  both slip 1.3%

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))